New recommendations for retinal monitoring in hydroxychloroquine users: baseline testing is no longer supported

Br J Dermatol. 2021 Aug;185(2):435-438. doi: 10.1111/bjd.20073. Epub 2021 May 9.

Authors

I H Yusuf^{1

2}, F Latheef³, M Ardern-Jones^{4

5}, A J Lotery⁴

Affiliations

¹ Nuffield Laboratory of Ophthalmology, Oxford University, Oxford, UK.
² Oxford Eye Hospital, Oxford, UK.
³ Leeds Centre for Dermatology, Chapel Allerton Hospital, Leeds, UK.
⁴ Clinical Experimental Sciences, University of Southampton, Southampton, UK.
⁵ Department of Dermatology, University Hospitals Southampton NHS Trust, Southampton, UK.

PMID: 33733454
DOI: 10.1111/bjd.20073

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antirheumatic Agents* / adverse effects
Humans
Hydroxychloroquine / adverse effects
Retina
Retinal Diseases* / chemically induced
Retinal Diseases* / diagnosis
Tomography, Optical Coherence

Substances

Antirheumatic Agents
Hydroxychloroquine

Grants and funding

MR/R000735/1/MRC_/Medical Research Council/United Kingdom